Sort   by:  
 Page size 
MetabolomicsSex Differences in Colon Cancer Metabolism Reveal A Novel Subphenotype (UPLC-MS HILIC NEG assay)

Women have a lower incidence of colorectal cancer (CRC) than men, however, they have a higher incidence of right-sided colon cancer (RCC). This is of concern as patients with RCC have the poorest clinical outcomes among all CRC patients. Aberrant metabolism is a known hallmark and therapeutic tar...

2020-03-19 | MTBLS1124 | MetaboLights
MetabolomicsSex Differences in Colon Cancer Metabolism Reveal A Novel Subphenotype (UPLC-MS RP POS assay)

Women have a lower incidence of colorectal cancer (CRC) than men, however, they have a higher incidence of right-sided colon cancer (RCC). This is of concern as patients with RCC have the poorest clinical outcomes among all CRC patients. Aberrant metabolism is a known hallmark and therapeutic tar...

2020-03-19 | MTBLS1129 | MetaboLights
MetabolomicsSex Differences in Colon Cancer Metabolism Reveal A Novel Subphenotype (UPLC-MS RP NEG assay)

Women have a lower incidence of colorectal cancer (CRC) than men, however, they have a higher incidence of right-sided colon cancer (RCC). This is of concern as patients with RCC have the poorest clinical outcomes among all CRC patients. Aberrant metabolism is a known hallmark and therapeutic tar...

2020-03-19 | MTBLS1130 | MetaboLights
MetabolomicsSex Differences in Colon Cancer Metabolism Reveal A Novel Subphenotype (UPLC-MS HILIC POS assay)

Women have a lower incidence of colorectal cancer (CRC) than men, however, they have a higher incidence of right-sided colon cancer (RCC). This is of concern as patients with RCC have the poorest clinical outcomes among all CRC patients. Aberrant metabolism is a known hallmark and therapeutic tar...

2020-03-19 | MTBLS1122 | MetaboLights
MetabolomicsDistinct microbes, metabolites, and the host genome define the multi-omics profiles in right-sided and left-sided colon cancer

BACKGROUND: Studies have reported clinical heterogeneity between right-sided colon cancer (RCC) and left-sided colon cancer (LCC). However, none of these studies used multi-omics analysis combining genetic regulation, microbiota and metabolites to explain the site-specific differ...

2024-12-16 | MTBLS10232 | MetaboLights
ProteomicsProteogenomic characterization of human colon and rectal cancer
Explore This Study at the NCI Proteomic Data Commons

Zhang, B., et al., Nature (2014) do...

ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2019-08-26 | MSV000084238 | MassIVE
ProteomicsPROTEOMIC ALTERATIONS IN COLON ADENOCARCINOMA TISSUE LYSATES
Colorectal cancer is the third most common cancer worldwide, with 1.4 million people diagnosed in 2012 according to GLOBOCAN 2012. 95% of the colon cancer cases are that of adenocarcinomas. Removal of high-risk adenomas and tumors at early stage of colorectal cancer (CRC) can prevent its onset/progr...
ORGANISM(S): Homo sapiens (Human) 
2018-03-28 | PXD006509 | Pride
Human Lc-ms Mrm Colon adenocarcinoma Itraq 
MetabolomicsExtracts from sweet sorghum (Sorghum bicolor), a feedstock for biorefining, suppressed proliferation and elevated apoptosis in human colon cancer stem cells via suppression of Wnt/beta-catenin signaling pathway
In colorectal cancer, p53 is commonly inactivated, associated with chemo-resistance, and marks the transition from non-invasive to invasive disease. Cancers, including colorectal cancer, are thought to be diseases of aberrant stem cell populations, as stem cells are able to self-renew, making them l...
2014-05-01 | MTBLS69 | MetaboLights
MetabolomicsSpatial and Untargeted Metabolomics Define Location- and Histology-Specific Metabolic Reprogramming in Colorectal Cancer

Colorectal cancer (CRC) exhibits profound molecular heterogeneity based on primary tumor location. A comprehensive understanding of the spatially resolved metabolic differences between right-sided (RCC) and left-sided (LCC) carcinomas remains elusive. Here, to eliminate the influence of inter-ind...

2026-03-24 | MTBLS13729 | MetaboLights
TranscriptomicsNew specific molecular targets for radiochemotherapy in colorectal cancer
A promising treatment for patients with advanced colorectal cancer is preoperative radiochemotherapy. The early side effects of this treatment have been considered to be acceptable. The aim of this study was to identify the effects of preoperative radiochemotherapy (PRT) on gene expression in tumour...
ORGANISM(S): Homo sapiens 
2010-04-09 | E-GEOD-15781 | biostudies-arrayexpress
Sort   by:  
 Page size